BACKGROUND: Current US guidelines recommend limiting hepatitis C virus (HCV) screening to high-risk individuals, and 50%-75% of infected persons remain unaware of their status. METHODS: To estimate the cost-effectiveness and population-level impact of adding one-time HCV screening of US population aged 20-69 years to current guidelines, we developed a decision analytic model for the screening intervention and Markov model with annual transitions to estimate natural history. Subanalyses included protease inhibitor therapy and screening those at highest risk of infection (birth year 1945-1965). We relied on published literature and took a lifetime, societal perspective. RESULTS: Compared to current guidelines, incremental cost per quality-adjusted life year gained (ICER) was $7900 for general population screening and $4200 for screening by birth year, which dominated general population screening if cost, clinician uptake, and median age of diagnoses were assumed equivalent. General population screening remained cost-effective in all one-way sensitivity analyses, 30 000 Monte Carlo simulations, and scenarios in which background mortality was doubled, all genotype 1 patients were treated with protease inhibitors, and most parameters were set unfavorable to increased screening. ICER was lowest if screening was applied to a population with liver fibrosis similar to 2010 estimates. Approximately 1% of liver-related deaths would be averted per 15% of the general population screened; the impact would be greater with improved referral, treatment uptake, and cure. CONCLUSIONS: Broader screening for HCV would likely be cost-effective, but significantly reducing HCV-related morbidity and mortality would also require improved rates of referral, treatment, and cure.
BACKGROUND: Current US guidelines recommend limiting hepatitis C virus (HCV) screening to high-risk individuals, and 50%-75% of infected persons remain unaware of their status. METHODS: To estimate the cost-effectiveness and population-level impact of adding one-time HCV screening of US population aged 20-69 years to current guidelines, we developed a decision analytic model for the screening intervention and Markov model with annual transitions to estimate natural history. Subanalyses included protease inhibitor therapy and screening those at highest risk of infection (birth year 1945-1965). We relied on published literature and took a lifetime, societal perspective. RESULTS: Compared to current guidelines, incremental cost per quality-adjusted life year gained (ICER) was $7900 for general population screening and $4200 for screening by birth year, which dominated general population screening if cost, clinician uptake, and median age of diagnoses were assumed equivalent. General population screening remained cost-effective in all one-way sensitivity analyses, 30 000 Monte Carlo simulations, and scenarios in which background mortality was doubled, all genotype 1 patients were treated with protease inhibitors, and most parameters were set unfavorable to increased screening. ICER was lowest if screening was applied to a population with liver fibrosis similar to 2010 estimates. Approximately 1% of liver-related deaths would be averted per 15% of the general population screened; the impact would be greater with improved referral, treatment uptake, and cure. CONCLUSIONS: Broader screening for HCV would likely be cost-effective, but significantly reducing HCV-related morbidity and mortality would also require improved rates of referral, treatment, and cure.
Authors: Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas Journal: J Community Health Date: 2008-06
Authors: Bart J Veldt; E Jenny Heathcote; Heiner Wedemeyer; Juerg Reichen; W Peter Hofmann; Stefan Zeuzem; Michael P Manns; Bettina E Hansen; Solko W Schalm; Harry L A Janssen Journal: Ann Intern Med Date: 2007-11-20 Impact factor: 25.391
Authors: Holly Groom; Eric Dieperink; David B Nelson; Judith Garrard; James R Johnson; Stephen L Ewing; Herbert Stockley; Janet Durfee; Yvonne Jonk; Mark L Willenbring; Samuel B Ho Journal: J Clin Gastroenterol Date: 2008-01 Impact factor: 3.062
Authors: Mitchell L Shiffman; Fredy Suter; Bruce R Bacon; David Nelson; Hugh Harley; Ricard Solá; Stephen D Shafran; Karl Barange; Amy Lin; Ash Soman; Stefan Zeuzem Journal: N Engl J Med Date: 2007-07-12 Impact factor: 91.245
Authors: J Thompson Coon; G Rogers; P Hewson; D Wright; R Anderson; S Jackson; S Ryder; M Cramp; K Stein Journal: Br J Cancer Date: 2008-04-01 Impact factor: 7.640
Authors: Andrew J Leidner; Harrell W Chesson; Philip R Spradling; Scott D Holmberg Journal: Appl Health Econ Health Policy Date: 2017-02 Impact factor: 2.561
Authors: Alexis P Chidi; Cindy L Bryce; Julie M Donohue; Michael J Fine; Douglas P Landsittel; Larissa Myaskovsky; Shari S Rogal; Galen E Switzer; Allan Tsung; Kenneth J Smith Journal: Value Health Date: 2016-03-24 Impact factor: 5.725
Authors: Jason E Stout; Shereen Katrak; Neela D Goswami; Brianna L Norton; Ellen R Fortenberry; Evelyn Foust; Peter A Leone Journal: Public Health Rep Date: 2014 Jan-Feb Impact factor: 2.792
Authors: Mina Kabiri; Alison B Jazwinski; Mark S Roberts; Andrew J Schaefer; Jagpreet Chhatwal Journal: Ann Intern Med Date: 2014-08-05 Impact factor: 25.391